📈 Jumpstart Signal Watchlist — July 17, 2026

🏢 What they do: Taboola is an advertising technology company that operates a two-sided platform connecting advertisers with audiences across publisher websites and digital properties on the open web, using machine learning to match ads and content recommendations with users .
- 🎯 Current $5.28 is 5% below 3yr high $5.58 · ⏳ SMA200 $3.97 (current price $5.28 is above) · 💰 Market Cap $1.5B
- TBLA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 767% (>20%); Low LT D/E 0.07 (<1.0); PEG ratio 0.02 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Taboola stock hits 52-week high at 5.26 USD — Investing.com.
🤖 The stock hit a 52-week high of $5.26, surging 86% from its low, and reported Q1 2026 earnings that significantly beat expectations with $0.20 EPS versus a predicted loss, plus revenue of $466.4M exceeding forecasts.
✅ Hsbc Holdings PLC Takes $887000 Position in Taboola — MarketBeat.
🤖 HSBC Holdings PLC established an $887,000 position in Taboola, reinforcing institutional confidence while the stock maintains a 'Moderate Buy' consensus with an average target price of $5.90.
✅ Taboola股價創52週新高，報5.26美元 — Investing.com (HK).
🤖 Taboola's stock reached a 52-week high of $5.26, reflecting strong investor confidence after Q1 2026 earnings beat expectations with $0.20 EPS and $466.4M revenue, while analysts view the stock as undervalued with a fair value of $6.57.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: DiamondRock Hospitality Company (DRH) is a self-advised real estate investment trust (REIT) that owns a portfolio of approximately 35-36 premium hotels and resorts with about 9,600 rooms, concentrated in U.S. gateway markets and leisure destinations.
- 🎯 At/above 3yr high $12.55 (current $12.55) · ⏳ SMA200 $9.71 (current price $12.55 is above) · 💰 Market Cap $2.6B
- DRH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (10.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 75% (>20%); Low LT D/E 0.76 (<1.0); PEG ratio 0.36 (<1.5).
⏰ Entry (E): 2/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Diamondrock Hospitality stock hits 52-week high at 12.54 USD — Investing.com.
🤖 The stock reached a 52-week high of $12.54, signaling strong market performance and investor confidence in DiamondRock Hospitality.
✅ DiamondRock Hospitality (NYSE:DRH) Sees Strong Trading Volume — MarketBeat.
🤖 DRH closed at $12.55 with a 2.20% gain and strong trading volume on July 17, 2026, indicating active investor interest and upward momentum.
⚪️ DiamondRock Hospitality Stock Is Up 61%. Here's What This Insider Sale Could Mean — The Motley Fool.
🤖 While the stock is up 61%, the article discusses an insider sale of 20,000 shares by Director Kathleen Merrill, which could be interpreted as neutral given the strong price appreciation offsets typical insider sale concerns.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Sunstone Hotel Investors, Inc. is a lodging real estate investment trust (REIT) that acquires, actively owns, and disposes of well-located hotel and resort real estate to create long-term stakeholder value. The company owns a geographically diverse portfolio of 15 upper upscale and luxury hotels, the majority of which are operated under nationally recognized brands.
- 🎯 Current $11.73 is 5% below 3yr high $12.38 · ⏳ SMA200 $9.68 (current price $11.73 is above) · 💰 Market Cap $2.2B
- SHO shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (8.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 700% (>20%); Low LT D/E 0.50 (<1.0); PEG ratio 0.15 (<1.5).
⏰ Entry (E): 0/20
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 4/10
- 🗞️ News sentiment is negative (mixed coverage).
✅ Sunstone Hotel Investors enters into an agreement to sell Hyatt Regency San Francisco — PR Newswire.
🤖 Sunstone announced a definitive agreement to sell the 821-room Hyatt Regency San Francisco to Blackstone Real Estate for $279 million, approximately $340,000 per key, representing a 21.4x multiple on Hotel Adjusted EBITDAre, which is a positive asset monetization.
❌ Sunstone hotel investors CIO Robert Springer sells $1.04m in shares — Investing.com.
🤖 President and CIO Robert Springer sold 89,631 shares for $1.04 million on June 24, 2026, which is typically viewed as a negative signal for investors despite the stock trading near its 52-week high.
❌ Sunstone Hotels President Unloads 89,000 Shares. Is This a Red Flag for Investors? — The Motley Fool.
🤖 The article questions whether the President's sale of 89,631 shares is a red flag for investors, framing the insider selling as potentially negative for the stock.
⚪️ Sunstone Hotel Investors Q2 2026 Earnings Report — MarketBeat.
🤖 This article only provides the upcoming Q2 2026 earnings report date and current stock price without actual financial results, guidance, or analyst opinion, making it a bare date announcement that must be omitted; however, since it was included in search results as a report page, it is neutral as it lacks substantive news content.
🍭 Bonus (B): 0/10 — Hotels & Motels

🏢 What they do: Metallus Inc. manufactures specialty steel and metal products, including alloy steel bars, seamless mechanical tubing, precision steel components, and billets. Its products are used in demanding industrial, automotive, aerospace & defense, and energy applications.
- 🎯 Current $19.38 is 19% below 3yr high $24.02 · ⏳ SMA200 $18.09 (current price $19.38 is above) · 💰 Market Cap $969M
- MTUS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 333% (>20%); Low LT D/E 0.00 (<1.0); PEG ratio 0.83 (<1.5).
⏰ Entry (E): 2/20
- 📈 RSI at 52 in healthy mid-range
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Emerald Mutual Fund Advisers Trust Takes $3.89 Million Position in Metallus Inc (MTUS) — MarketBeat.
🤖 Emerald Mutual Fund Advisers Trust acquired a $3.89 million position in Metallus, signaling institutional confidence and adding buying pressure to the stock.
✅ Metallus (MTUS) Tops Q1 Earnings and Revenue Estimates — Zacks.
🤖 Metallus reported Q1 earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.13, demonstrating strong operational performance despite revenue being below some expectations.
⚪️ Metallus Announces Second-Quarter 2026 Earnings Webcast Details — PRNewswire.
🤖 The company confirmed its Q2 2026 earnings release date (August 3) and webcast schedule, which is standard operational transparency without immediate financial impact.
🍭 Bonus (B): 0/10 — Steel Works & Blast Furnaces

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $12.06 is 12% below 3yr high $13.71 · ⏳ SMA200 $8.50 (current price $12.06 is above) · 💰 Market Cap $812M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); ROE 15% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.15 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (9.7%)
- 🔔 Strong above EMA50 (17.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Bioventus (NASDAQ:BVS) Reaches New 12-Month High - Here's Why — MarketBeat.
🤖 The stock reached a new 12-month high with a consensus 'Buy' rating and a price target of $14.75, indicating strong analyst confidence and upward momentum for $BVS[1].
✅ Bioventus shares rise after Medicare reverses reimbursement cuts — Investing.com.
🤖 Shares climbed up to 13% after the Centers for Medicare & Medicaid Services reversed previously issued reimbursement cuts for Bioventus's non-invasive bone growth stimulators, directly improving revenue potential[2].
✅ Saham Bioventus naik setelah Medicare batalkan pemotongan reimbursmen — Investing.com.
🤖 This Indonesian-language report confirms the same positive event as the English version: Bioventus shares rose 13% following Medicare's reversal of reimbursement cuts for its bone growth stimulators[3].
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $55.92 is 2% below 3yr high $57.10 · ⏳ SMA200 $44.80 (current price $55.92 is above) · 💰 Market Cap $14.2B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (10.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 44% (>20%); ROE 43% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Allspring Global Investments Holdings LLC Acquires 32,389 Shares of Exelixis, Inc. $EXEL — MarketBeat.
🤖 Allspring Global Investments increased its stake in Exelixis, signaling institutional confidence, while the article highlights Exelixis' strong Q1 2026 earnings beat of $0.87 EPS versus $0.75 expected and 10% revenue growth.
✅ Assetmark Inc. Increases Stake in Exelixis, Inc. $EXEL — MarketBeat.
🤖 Assetmark Inc. increased its holdings in Exelixis, reflecting institutional buying interest, though the article notes the stock currently carries a consensus 'Hold' rating with a price target below the current trading price.
❌ EXEL Down on Colorectal Cancer Study Data on Zanzalintinib — Zacks.
🤖 Exelixis shares fell 1.08% after the STELLAR-303 trial failed to achieve statistical significance on its second dual primary endpoint for overall survival in patients without active liver metastases, despite a positive trend favoring the combination therapy.
⚪️ Morgan Stanley reiterates Exelixis stock rating on mixed trial data — Investing.com.
🤖 Morgan Stanley maintained an Equalweight rating and $50 price target following mixed STELLAR-303 trial data, while the article also notes Exelixis' strong Q1 2026 financial results and a new Merck collaboration for a phase 3 KEYTRUDA trial.
⚪️ Exelixis, Inc. (NASDAQ:EXEL) Given Consensus Recommendation of Hold by Analysts — MarketBeat.
🤖 Analysts from 20 firms assigned a consensus 'Hold' rating to Exelixis, with an equal split of 9 buy and 9 hold ratings alongside 2 sell ratings, indicating balanced but cautious market sentiment.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: A10 Networks is an American public company specializing in application delivery controllers and cybersecurity solutions for on-premises, cloud, and edge environments. The company provides software and hardware products that secure applications, networks, and infrastructure from cyber threats while optimizing performance and availability across hybrid cloud architectures.
- 🎯 Current $35.96 is 6% below 3yr high $38.11 · ⏳ SMA200 $22.81 (current price $35.96 is above) · 💰 Market Cap $2.6B
- ATEN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (9.5% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 31% (>20%); ROE 20% (>15%); Low LT D/E 0.99 (<1.0).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (10.0%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (56) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ A10 Networks (NYSE:ATEN) Sets New 12-Month High - Still a Buy? — MarketBeat.
🤖 The stock hit a new 52-week high of $38.40, signaling strong momentum, though the consensus rating remains 'Hold' with a price target below the current share price.
✅ BTIG raises A10 Networks stock price target to $37 on AI tailwinds — Investing.com.
🤖 BTIG increased its price target from $30 to $37 and maintained a 'Buy' rating, citing strong Q1 2026 earnings (EPS $0.24 vs. $0.23 forecast), revenue of $75M, and the acquisition of AI security firm TrojAI.
⚪️ Boston Trust Walden Corp Has $50.25 Million Stake in A10 Networks, Inc. (ATEN) — MarketBeat.
🤖 Boston Trust Walden Corp owns approximately 3.03% of A10 Networks worth $50.25 million, indicating institutional confidence, though the stock dipped 4.4% and the consensus rating remains 'Hold'.
🍭 Bonus (B): 10/10 — Computer Communications Equipment (Technology sector)

🏢 What they do: BrightSpring Health Services (BTSG) is a leading provider of comprehensive home and community-based health services, including clinical, nonclinical, pharmacy, and ancillary care, to complex populations across all ages and skill levels. It operates as the parent company of brands focused on specialized care in home and community settings, emphasizing quality outcomes for people with complex needs.
- 🎯 Current $70.69 is 1% below 3yr high $71.58 · ⏳ SMA200 $43.74 (current price $70.69 is above) · 💰 Market Cap $13.7B
- BTSG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 Low drawdown (9.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 379% (>20%); Revenue growth 26% (>15%); ROE 16% (>15%).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (12.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ BTSG Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised — Zacks.
🤖 BrightSpring Health Services beat Q1 2026 adjusted EPS expectations by 34.5% (39 cents vs. 29 cents consensus) and raised its 2026 outlook, driving stock gains.
🍭 Bonus (B): 0/10 — Home Health Care Services

🏢 What they do: Remitly Global, Inc. is a digital financial services provider that offers cross-border remittance and international money transfer services primarily for immigrants and their families through a mobile app and website .
- 🎯 Current $24.13 is 12% below 3yr high $27.59 · ⏳ SMA200 $17.01 (current price $24.13 is above) · 💰 Market Cap $5.1B
- RELY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 360% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.00 (<1.0); PEG ratio 0.14 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (10.9%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (60) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Citizens raises Remitly stock price target to $30 on growth outlook — Investing.com.
🤖 Citizens raised its price target on Remitly Global to $30 from $26 while maintaining a Market Outperform rating, signaling strong confidence in the company's growth trajectory and core remittance business[10].
✅ Here's Why Remitly Global Jumped 62.4% In The First Half of 2026 — The Motley Fool.
🤖 Remitly Global shares surged 62.4% in the first half of 2026, reflecting significant investor confidence and strong performance despite a recent 4.20% daily drop[3].
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Host Hotels & Resorts, Inc. (HST) is the world's largest publicly traded lodging real estate investment trust (REIT). It owns a geographically diverse portfolio of luxury and upper-upscale hotels, primarily in top U.S. markets, and is the largest third-party owner of Marriott and Hyatt hotels.
- 🎯 Current $23.94 is 5% below 3yr high $25.13 · ⏳ SMA200 $19.64 (current price $23.94 is above) · 💰 Market Cap $16.4B
- HST shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (9.4% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 106% (>20%); Low LT D/E 0.19 (<1.0); PEG ratio 0.15 (<1.5).
⏰ Entry (E): 0/20
- 📈 RSI at 55 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Stifel reiterates Buy rating on Host Hotels stock at $26.25 — Investing.com.
🤖 Stifel maintained its Buy rating with a $26.25 price target, highlighting robust second-quarter trends and strong leisure demand, which signals analyst confidence in $HST's near-term performance.
✅ Host Hotels Resorts आम सहमति आकलन (HST) - Investing.com भारत — Investing.com India.
🤖 The consensus rating for $HST is 'Buy' based on 20 analysts, with 12 recommending a purchase and none suggesting a sell, indicating strong overall analyst support for the stock.
🍭 Bonus (B): 0/10 — REITs